General
Information
Last Update:
Mar. 10, 2011
bottom of page
Part of the audited Consolidated Financial Statements and Management´s Analysis

Business review

Sales by division

Performance Products – Sales by division (pie chart)

Sales to third parties increased by €2,932 million to €12,288 million (volumes 12%, prices 4%, portfolio 11%, currencies 4%). This positive business development can be attributed to strong demand and the full-year inclusion of the integrated Ciba businesses as well as the acquisition of Cognis on December 9, 2010. Income from operations rose by €1,495 million to €1,345 million – despite the negative impact of one-time costs at year-end. This was due to our successful measures to integrate Ciba and restructure the combined businesses as well as the considerable increase in volumes.

In 2011, we expect stable demand and – boosted by the Cognis acquisition – substantial sales growth. We aim for a strong increase in earnings.

Sales – Performance Products
(million €)

Performance Products – Sales (bar chart)

Factors influencing sales – Performance Products

Performance Products – Factors influencing sales (bar chart)

Income from operations – Performance Products
(million €)

Performance Products – Income from operations (bar chart)
  Download (Download XLS xls, 18 kB)

Segment data Performance Products (million €)

 

 

2010

2009

Change in %

Sales to third parties

12,288

9,356

31.3

Thereof Dispersions & Pigments

3,197

2,445

30.8

Care Chemicals

2,755

2,067

33.3

Nutrition & Health

1,482

1,338

10.8

Paper Chemicals

1,713

1,326

29.2

Performance Chemicals

3,141

2,180

44.1

Intersegmental transfers

438

319

37.3

Sales including intersegmental transfers

12,726

9,675

31.5

Income from operations before depreciation and amortization (EBITDA)

2,162

926

133.5

EBITDA margin (%)

17.6

9.9

Income from operations (EBIT) before special items

1,554

698

122.6

Income from operations (EBIT)

1,345

(150)

.

Income from operations (EBIT) after cost of capital

441

(930)

.

Assets

13,409

9,242

45.1

Research and development expenses

289

285

1.4

Additions to property, plant and equipment and intangible assets

3,000

3,753

(20.1)

previous page top of page next page